Anil Ranganath Sells 864 Shares of TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Anil Ranganath sold 864 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $139.12, for a total value of $120,199.68. Following the sale, the insider owned 13,091 shares in the company, valued at approximately $1,821,219.92. The trade was a 6.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

TransMedics Group Price Performance

Shares of TMDX opened at $140.07 on Friday. The firm has a market cap of $4.80 billion, a PE ratio of 28.59 and a beta of 1.98. TransMedics Group, Inc. has a 52-week low of $62.07 and a 52-week high of $156.00. The business’s 50 day moving average price is $135.24 and its two-hundred day moving average price is $126.87. The company has a debt-to-equity ratio of 1.06, a quick ratio of 6.59 and a current ratio of 7.14.

More TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Wall‑street support — several firms recently raised price targets and maintained buy/overweight ratings, which boosts headline upside and institutional interest. MarketBeat Analyst Coverage
• Positive Sentiment: Technical setup — Investors.com flags a cup‑with‑handle with a buy point at $151.85; a decisive breakout above that level could trigger momentum buying and validate the technical thesis. Medical Stock Nears Buy Point Amid Liver Transplant Demand Surge
• Neutral Sentiment: Institutional backing — large positions from Vanguard, UBS, Goldman and others mean strong liquidity and long‑term holders, which can stabilize shares but don’t eliminate short‑term swings. MarketBeat Institutional Holdings
• Negative Sentiment: Insider selling — multiple insiders including CFO Gerardo Hernandez sold sizeable blocks this week (notably a 7,236‑share sale at ~$147.21 on Mar 4 plus other disposals), and other insiders trimmed positions; concentrated insider exits are likely a near‑term headwind for sentiment. TransMedics Group (NASDAQ:TMDX) CFO Sells $52,170.00 in Stock

Analyst Ratings Changes

Several brokerages have recently weighed in on TMDX. JPMorgan Chase & Co. upped their price objective on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Canaccord Genuity Group upped their price target on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Oppenheimer raised their price objective on TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Morgan Stanley upped their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Finally, Needham & Company LLC boosted their price target on shares of TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $150.67.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently bought and sold shares of TMDX. Royal Bank of Canada grew its stake in shares of TransMedics Group by 47.9% in the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after acquiring an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of TransMedics Group by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after purchasing an additional 868 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after purchasing an additional 86,721 shares during the last quarter. Envestnet Asset Management Inc. grew its position in TransMedics Group by 12.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 26,298 shares of the company’s stock worth $3,524,000 after purchasing an additional 2,933 shares in the last quarter. Finally, Atria Investments Inc purchased a new stake in TransMedics Group in the 2nd quarter valued at about $213,000. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.